**Antimicrobials Evaluation Committee Meeting**

**Minutes:** Unconfirmed

**Date and Time:** Friday 11 February 2022 at 9am

|  |  |  |  |
| --- | --- | --- | --- |
| **Present:** | 1. Amanda Adler (Chair) | | Present for all notes |
|  | 1. Colin Brown | | Present for all notes |
|  | 1. Mark Chapman | | Present for all notes |
|  | 1. Veline Esperance | | Present for all notes |
|  | 1. Tim Felton | | Present for all notes |
|  | 1. Neil Ferguson | | Present for all notes |
|  | 1. Neil Hawkins | | Present for all notes |
|  | 1. Andrew Hitchings (Vice chair) | | Present for all notes |
|  | 1. Alison Holmes | | Present for all notes |
|  | 1. Philip Howard | | Present for all notes |
|  | 1. Peter Jackson | | Present for all notes |
|  | 1. Alistair Leanord | | Present for all notes |
|  | 1. Patrick McGinley | | Present for all notes |
|  | 1. Malcolm Oswald | | Present for all notes |
|  | 1. David Partridge | | Present for all notes |
|  | 1. Matt Stevenson | | Present for all notes |
|  | 1. Nicky Welton | | Present for all notes |
| **In attendance:** | |  |  |
| Nick Crabb | | Programme Director, National Institute for Health and Care Excellence | Present for all notes |
| Sophie Cooper | | Scientific Adviser, National Institute for Health and Care Excellence | Present for all notes |
| Natalie Spray | | Project Manager, National Institute for Health and Care Excellence | Present for all notes |
| Pratit Shah | | Administrator, National Institute for Health and Care Excellence | Present for all notes |
| Caroline Bregman | | Technical Analyst, National Institute for Health and Care Excellence | Present for all notes |
| James Love-Koh | | Technical Analyst, National Institute for Health and Care Excellence | Present for all notes |
| Jacoline Bouvy | | Technical Director, National Institute for Health and Care Excellence | Present for all notes |
| Colm Leanord | | Consultant Clinical Advisor, National Institute for Health and Care Excellence | Present for all notes |
| Mandy Tonkinson | | NICE PIP representative, National Institute for Health and Care Excellence | Present for notes 1 to 4 |
|  | |  |  |
|  | |  |  |
| **Non-public attendees:** | |  |  |
| Nicola Andrews | | Anthony Nolan patient nomination,  Patient expert | Present for notes 1 to 4 |
|  | |  |  |
| Arlene Brailey | | Patient Support Team Lead, Antibiotic Research UK,  Patient expert | Present for notes 1 to 4 |
|  | |  |  |
| Warren Cowell | | Director, Market Access, Shionogi,  Company representative | Present for notes 1 to 4 |
|  | |  |  |
| Alicia Demirijian | | Infections Consultant, Epidemiologist, Evelina London Children’s Hospital,  Clinical expert | Present for notes 1 to 4 |
|  | |  |  |
| David Glover | | Assistant Director of Medicines Analysis, Medicines Policy Unit, NHS England and NHS Improvement,  NHS commissioning expert | Present for notes 1 to 4 |
|  | |  |  |
| Anna Goodman | | Infectious Diseases Consultant, Guy’s and St Thomas’ NHS Foundation Trust, Clinical expert | Present for notes 1 to 4 |
|  | |  |  |
| Sue Harnan | | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  | |  |  |
| Peter Hawkey | | Professor Emeritus of Clinical & Public Health, Locum Consultant Microbiologist,  Company representative | Present for notes 1 to 4 |
|  | |  |  |
| Dina Jankovic | | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  | |  |  |
| Ben Kearns | | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  | |  |  |
| Christopher Longshaw | | Senior Director, Scientific Affairs, Shionogi,  Company representative | Present for notes 1 to 4 |
|  | |  |  |
| Mark Perkins | | Head of Strategic Category Management, Commercial Medicines Directorate, NHS England & Improvement | Present for notes 1 to 4 |
|  | |  |  |
| Mark Sculpher | | Project team, Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) | Present for notes 1 to 4 |
|  | |  |  |
| Oliver Troise | | Lead Antimicrobial Pharmacist, West Middlesex University Hospital, Chelsea and Westminster Hospital NHS Foundation Trust,  Clinical Expert | Present for notes 1 to 4 |

**Notes**

**Any other Business**

1. None

**Appraisal of cefiderocol for treating severe aerobic Gram-negative bacterial infections**

**Part 1 – Open session**

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (EEPRU) representatives and representatives from Shionogi.
2. (Link to committee register of interests)

The Chair asked all committee members, experts, EEPRU representatives and NICE staff present to declare any relevant interests that had not already been recorded on the register.

* 1. No further conflicts of interest were declared for this appraisal.

1. Presentation by the Chair and Lead Team: Malcolm Oswald, Phil Howard and Nicky Welton.
2. The committee considered the evidence submitted by Shionogi (the company that manufactures cefiderocol) and other stakeholders, the assessment report from the Policy Research Unit in Economic Methods of Evaluation in Health and Social Care Interventions (EEPRU), and consultation comments on EEPRU’s report from stakeholders. See the committee papers for full details of the evidence. The committee agreed its preferred approach to estimating the benefits of cefiderocol based on the options presented by EEPRU. The committee also considered whether EEPRU’s economic analysis had underestimated the benefits of cefiderocol, and estimated the size of the population eligible for cefiderocol.

**Part 2 – Closed session (company representatives, clinical and patient experts, EEPRU representatives and members of the public were asked to leave the meeting)**

1. The committee agreed the content of the draft guidance, including:

* the population eligible for cefiderocol, including recommendations on good antimicrobial stewardship
* the most plausible estimate of the incremental population net health benefits of cefiderocol to the NHS over the modelled time horizon, measured in quality-adjusted life years (QALYs)
* what proportion of the total incremental population net health benefits NHS England should assign to the contract period, in QALYs
* recommendations for research and data collection.

1. The committee’s conclusions and recommendations were based on majority opinion.
2. The committee asked the NICE technical team to prepare the draft guidance document in line with their decisions.